141 related articles for article (PubMed ID: 6358418)
1. Biologicals: new horizons in pharmaceutical development.
Oldham RK
J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
[No Abstract] [Full Text] [Related]
2. Findings halt clinical trials of centoxin.
Wagner M
Mod Healthc; 1993 Jan; 23(4):16. PubMed ID: 10123669
[No Abstract] [Full Text] [Related]
3. FDA requires further trials for antiendotoxin monoclonal antibody products.
Am J Hosp Pharm; 1992 Aug; 49(8):1848, 1850. PubMed ID: 1442827
[No Abstract] [Full Text] [Related]
4. The right to a trial: Should dying patients have access to experimental drugs?
Groopman J
New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
[No Abstract] [Full Text] [Related]
5. Monoclonal antibody successes in the clinic.
Reichert JM; Rosensweig CJ; Faden LB; Dewitz MC
Nat Biotechnol; 2005 Sep; 23(9):1073-8. PubMed ID: 16151394
[TBL] [Abstract][Full Text] [Related]
6. Medical costs and the drug industry.
Schwartz H
Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
[No Abstract] [Full Text] [Related]
7. The regulation of drugs and biologics: fifty years into the future.
Kuhlik BN
Food Drug Law J; 2000; 55(1):21-5. PubMed ID: 12269358
[No Abstract] [Full Text] [Related]
8. Development of orphan products.
FDA Drug Bull; 1983 Apr; 13(1):2-4. PubMed ID: 6852406
[No Abstract] [Full Text] [Related]
9. Drug development in India.
Bajaj JS
Indian J Physiol Pharmacol; 1981; 25(2):95-104. PubMed ID: 7287145
[TBL] [Abstract][Full Text] [Related]
10. Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan C
Nat Biotechnol; 2008 Apr; 26(4):361-3. PubMed ID: 18391999
[No Abstract] [Full Text] [Related]
11. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
12. [Drug legislation 1976: cost analysis for the pharmaceutical industry].
Kopf R
Internist (Berl); 1980 Jun; 21(6):333-8. PubMed ID: 7005170
[No Abstract] [Full Text] [Related]
13. [Development of new drugs--the United States regulatory perspective, 1998].
Averbuch M; Levo Y
Harefuah; 1998 Dec; 135(12):638-40. PubMed ID: 10911502
[No Abstract] [Full Text] [Related]
14. Natural products to drugs: natural product derived compounds in clinical trials.
Butler MS
Nat Prod Rep; 2005 Apr; 22(2):162-95. PubMed ID: 15806196
[TBL] [Abstract][Full Text] [Related]
15. An overview of current programs on drug development and regulation for small ruminants--pharmaceutical industry perspective.
Terry M
Vet Hum Toxicol; 1993; 35 Suppl 2():12-3. PubMed ID: 8236759
[No Abstract] [Full Text] [Related]
16. Comments on license requirements and veterinary biologicals.
Baker LR
J Am Vet Med Assoc; 1972 Feb; 160(4):509-10. PubMed ID: 5030605
[No Abstract] [Full Text] [Related]
17. Continuous cell lines as substrates for biologicals. Draft position paper. Pharmaceutical Manufacturer's Association.
Dev Biol Stand; 1989; 70():285-7. PubMed ID: 2759355
[No Abstract] [Full Text] [Related]
18. Drug development history, "overview," and what are GCPs?
Heilman RD
Qual Assur; 1995 Mar; 4(1):75-9. PubMed ID: 8520867
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars legislation awakens data exclusivity debate.
Hutson S
Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
[No Abstract] [Full Text] [Related]
20. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
[Next] [New Search]
